MYGN Myriad Genetics Inc.

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.

  • The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.



  • The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET.

The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at . 

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact 

Matt Scalo 

(801) 584-3532 

 

Media Contact 

Kate Schraml

(224) 875-4493



EN
11/11/2025

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be available through live audio webcas...

5h / 19m 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Heredit...

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs 100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced —the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO). The...

November 10, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 Nati...

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterat...

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Th...

November 3, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to Ge...

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disord...

October 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch